Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Guardant Health to Develop Blood-Based Diagnostic Tests for AstraZeneca’s Tagrisso

By Guardant Health | December 17, 2018

Guardant Health signed a multi-year agreement with AstraZeneca to develop blood-based companion diagnostic (CDx) tests supporting the commercialization of AstraZeneca’s oncology portfolio based on Guardant’s comprehensive liquid biopsy platform.

Under the terms of the agreement, Guardant Health will develop and pursue FDA approval for a Guardant360 CDx test for Tagrisso (osimertinib), AstraZeneca’s third-generation epidermal growth factor receptor (EGFR) inhibitor in advanced non-small cell lung cancer (NSCLC). Use of the assay will help identify patients that may respond to Tagrisso via a minimally invasive blood test.

Guardant Health also will develop a plasma-based tumor mutational burden (TMB) score CDx test using GuardantOMNI to predict response to AstraZeneca immunotherapy and targeted therapies within its oncology portfolio. AstraZeneca presented TMB data using this device from the Phase III MYSTIC trial at the European Society for Medical Oncology (ESMO) Immuno-Oncology 2018 Congress.

The U.S. Food and Drug Administration has granted breakthrough designation to the GuardantOMNI diagnostic device for its proprietary plasma-based TMB score. The Guardant TMB scoring methodology is optimized for plasma-based testing by accounting for several factors, including tumor shedding, to maximize sensitivity and specificity.

The agreement allows for development of further liquid biopsy CDx tests for AstraZeneca’s other clinical development programs.

“Precision medicine is at the heart of our ambition to eliminate cancer as a cause of death,” said Ruth March, Ph.D., senior vicep resident of precision medicine and genomics for AstraZeneca’s Innovative Medicines and Early Development (IMED) biotech unit.

Since its introduction in 2014, the Guardant360 assay has been ordered more than 70,000 times to help inform which therapy may be effective for advanced-stage cancer patients with solid tumors. More than 80 peer-reviewed studies have been published addressing its analytical validity, clinical validity, and clinical utility in multiple tumor types.

For advanced NSCLC, Guardant360 is covered by Medicare and by several private payers, including Cigna and several Blue Cross Blue Shield plans. It was granted breakthrough device status by the FDA in February 2018, making it the first comprehensive liquid biopsy to receive a breakthrough device designation.

The GuardantOMNI assay applies the performance of Guardant360 to a much broader genomic footprint. The test covers biomarkers of interest across the oncology drug development pipeline, including biomarkers for immuno-oncology applications such as its proprietary TMB score.

(Source: Guardant Health)


Filed Under: Oncology

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis announces tislelizumab helped extend median overall survival in first-line advanced esophageal cancer 
Johnson & Johnson Janssen pharmaceutical business in the Pharma 50
Janssen gets positive CHMP opinion for Imbruvica for adults with untreated chronic lymphocytic leukemia
oncopeptides
Oncopeptides’ Pepaxti wins positive opinion from CHMP for multiple myeloma patients
DNA sequencer
Localizing next-generation sequencing testing for cancer patients

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50